Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RY12 | Q9H244 | 18/20 | 0.66 |
| ▸ | PGR | P06401 | 1/20 | 0.66 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.66 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.66 |
| ▸ | DRD1 | P21728 | 1/20 | 0.66 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.66 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.66 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.66 |
| ▸ | FPR3 | P25089 | 1/20 | 0.66 |
| ▸ | PDE4A | P27815 | 1/20 | 0.66 |
| ▸ | GPR183 | P32249 | 1/20 | 0.66 |
| ▸ | DRD3 | P35462 | 1/20 | 0.66 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.66 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.66 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.66 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.66 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.66 |
| ▸ | P2RY13 | Q9BPV8 | 1/20 | 0.66 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13192072 | 1.00 | P2RY12 (0.66) | P2RY12PGRADORA3CHRM1DRD1 | |
| SCHEMBL16802407 | 0.94 | P2RY12 (0.65) | P2RY12PGRADORA3CHRM1DRD1 | |
| SCHEMBL18674025 | 0.94 | P2RY12 (0.65) | P2RY12PGRADORA3CHRM1DRD1 | |
| SCHEMBL14781683 | 0.94 | P2RY12 (0.65) | P2RY12PGRADORA3CHRM1DRD1 | |
| SCHEMBL17679482 | 0.94 | P2RY12 (0.65) | P2RY12PGRADORA3CHRM1DRD1 | |
| SCHEMBL29687890 | 0.94 | P2RY12 (0.65) | P2RY12PGRADORA3CHRM1DRD1 | |
| SCHEMBL14895049 | 0.94 | P2RY12 (0.65) | P2RY12PGRADORA3CHRM1DRD1 | |
| SCHEMBL18674062 | 0.94 | P2RY12 (0.65) | P2RY12PGRADORA3CHRM1DRD1 | |
| SCHEMBL13192517 | 0.93 | P2RY12 (0.64) | P2RY12PGRADORA3CHRM1DRD1 | |
| SCHEMBL16802375 | 0.93 | P2RY12 (0.64) | P2RY12PGRADORA3CHRM1DRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1135391-B1 | NOVEL TRIAZOLO(4,5-D)PYRIMIDINE COMPOUNDS | ASTRAZENECA AB (SE) | 2004-03-17 | — | — | EP | claimed |
| US-9056838-B2 | Intermediates and processes for preparing Ticagrelor | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2015-06-16 | — | — | US | disclosed |
| US-9056838-B2 | Intermediates and processes for preparing Ticagrelor | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2015-06-16 | — | — | US | disclosed |
| WO-2012138981-A2 | NEW INTERMEDIATES AND PROCESSES FOR PREPARING TICAGRELOR | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2012-10-11 | — | — | WO | disclosed |
| US-20100168156-A1 | Novel Benzoxathiine Derivative | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2010-07-01 | — | — | US | disclosed |
| US-20070293513-A1 | Cristalline and amorphous form of a triazolo (4,5-d) pyridimine compound | ASTRAZENECA AB (SE) | 2007-12-20 | — | — | US | disclosed |
| US-20070173518-A1 | CRISTALLINE AND AMORPHOUS FORM OF A TRIAZOLO (4,5-D) PYRIDIMINE COMPOUND | ASTRAZENECA AB (SE) | 2007-07-26 | — | — | US | disclosed |
| EP-1289992-B1 | NEW CRYSTALLINE FORM OF A TRIAZOLO(4,5-D)PYRIMIDINE COMPOUND | ASTRAZENECA AB (SE) | 2006-03-15 | — | — | EP | disclosed |
| EP-1493745-A1 | New crystalline and amorphous form of a triazolo(4,5-D)pyrimidine compound | AstraZeneca AB (SE) | 2005-01-05 | — | — | EP | disclosed |
| US-20030181469-A1 | Crystalline and amorphous form of a triazolo(4,5-d)pyrimidine compound | ASTRA ZENCA AB (SE) | 2003-09-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070293513-A1 | Cristalline and amorphous form of a triazolo (4,5-d) pyridimine compound | PNPO, MT-ND5, CYP3A5 | P2RY12 1838/4885PGR 3117/4885ADORA3 493/4885 |
| US-20100168156-A1 | Novel Benzoxathiine Derivative | XDH, GPR119, BRIX1 | P2RY12 2614/4885PGR 2057/4885ADORA3 981/4885 |
| US-20030181469-A1 | Crystalline and amorphous form of a triazolo(4,5-d)pyrimidine compound | TYMP, TYMS, DPYD | P2RY12 261/4885PGR 3490/4885ADORA3 197/4885 |
| US-20070173518-A1 | CRISTALLINE AND AMORPHOUS FORM OF A TRIAZOLO (4,5-D) PYRIDIMINE COMPOUND | MT-ND5, PNPO, PDXK | P2RY12 1894/4885PGR 2852/4885ADORA3 430/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.